Contact: Kathryn Ruehle, 914-740-2100, firstname.lastname@example.org
Which Interferons Best Control Viral Infections?
New Rochelle, NY, June 26, 2014—Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication. Important differences between the presence of IFN receptors on cells and new evidence that specific types of IFNs can control RNA virus infection are explored in a Review article in Journal of Interferon & Cytokine Research (JICR), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the JICR website.
In “Type-I and III Interferon Production in Response to RNA Viruses,” Elizabeth Reid and Bryan Charleston, The Pirbright Institute (Surrey, UK), review the most recent studies looking at how RNA virus infections are able to induce multiple signaling pathways in host cells. As a result, different types of interferons are produced, each with distinct antiviral properties.
“The interferon system plays a critical role in maintaining an optimum equilibrium between virus replication and host survival,” says Co-Editor-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, Ohio. “This review describes how RNA viruses achieve this balance by regulating the synthesis of Type I and Type III interferons.”
About the Journal
Journal of Interferon & Cytokine Research (JICR), led by Co-Editors-in-Chief Ganes C. Sen, PhD and Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, is an authoritative peer-reviewed journal published monthly online with Open Access options and in print that covers all aspects of interferons and cytokines from basic science to clinical applications. JICR is an official journal of the International Cytokine & Interferon Society. Complete tables of content and a sample issue may be viewed on the JICR website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.